{"id":33961,"date":"2025-11-11T15:24:36","date_gmt":"2025-11-11T09:54:36","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=33961"},"modified":"2025-11-11T15:24:38","modified_gmt":"2025-11-11T09:54:38","slug":"pharma-news-for-cogent-biosciences-anaptys-eledon","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-cogent-biosciences-anaptys-eledon","title":{"rendered":"Cogent Biosciences\u2019 Bezuclastinib Phase 3 PEAK Trial Positive Results for GIST; Domain Therapeutics Begins Phase I\/II Trial of CCR8 Inhibitor DT-7012 in Solid Tumors; Anaptys Reports Negative Phase 2 Outcomes for Rosnilimab in Ulcerative Colitis; QOL Medical Strikes Deal to Acquire Evoke Pharma for $11 Cash Per Share; Eledon Pharmaceuticals, Inc. Unveils Phase 2 BESTOW Trial Data for Tegoprubart in Kidney Transplant Rejection Prevention at ASN Kidney Week 2025"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a04a8b241ce0\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a04a8b241ce0\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-cogent-biosciences-anaptys-eledon\/#Cogent_Biosciences_Announces_Positive_Outcomes_from_the_Phase_3_PEAK_Trial_of_Bezuclastinib_in_Gastrointestinal_Stromal_Tumors\" >Cogent Biosciences Announces Positive Outcomes from the Phase 3 PEAK Trial of Bezuclastinib in Gastrointestinal Stromal Tumors<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-cogent-biosciences-anaptys-eledon\/#Domain_Therapeutics_Doses_First_Patients_in_Phase_III_Trial_of_DT-7012_Targeting_CCR8_in_Solid_Tumors\" >Domain Therapeutics Doses First Patients in Phase I\/II Trial of DT-7012 Targeting CCR8 in Solid Tumors<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-cogent-biosciences-anaptys-eledon\/#Anaptys_Reports_Phase_2_Study_of_Rosnilimab_in_Moderate-to-Severe_Ulcerative_Colitis_Failed_to_Achieve_Primary_or_Secondary_Endpoints_at_Week_12\" >Anaptys Reports Phase 2 Study of Rosnilimab in Moderate-to-Severe Ulcerative Colitis Failed to Achieve Primary or Secondary Endpoints at Week 12<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-cogent-biosciences-anaptys-eledon\/#Evoke_Pharma_Enters_into_Definitive_Agreement_to_Be_Acquired_by_QOL_Medical\" >Evoke Pharma Enters into Definitive Agreement to Be Acquired by QOL Medical<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-cogent-biosciences-anaptys-eledon\/#Eledon_Presents_Phase_2_BESTOW_Trial_Results_for_Tegoprubart_in_Kidney_Transplant_Rejection_Prevention_at_ASN_Kidney_Week_2025\" >Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart in Kidney Transplant Rejection Prevention at ASN Kidney Week 2025<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-cogent-biosciences-announces-positive-outcomes-from-the-phase-3-peak-trial-of-bezuclastinib-in-gastrointestinal-stromal-tumors\"><span class=\"ez-toc-section\" id=\"Cogent_Biosciences_Announces_Positive_Outcomes_from_the_Phase_3_PEAK_Trial_of_Bezuclastinib_in_Gastrointestinal_Stromal_Tumors\"><\/span><strong>Cogent Biosciences Announces Positive Outcomes from the Phase 3 PEAK Trial of Bezuclastinib in Gastrointestinal Stromal Tumors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Cogent Biosciences, Inc.<\/strong> announced positive topline results from its <strong>Phase 3 PEAK trial<\/strong> evaluating <strong>bezuclastinib plus sunitinib<\/strong> in patients with imatinib-resistant or intolerant <a href=\"https:\/\/www.delveinsight.com\/report-store\/gastrointestinal-stromal-tumor-gist-market\">Gastrointestinal Stromal Tumors (GIST)<\/a>. The combination therapy achieved a median progression-free survival (mPFS) of 16.5 months, compared to 9.2 months for sunitinib alone (HR=0.50, 95% CI: 0.39\u20130.65; p&lt;0.0001). The objective response rate (ORR) was also higher with the combination (46%) versus 26% for monotherapy (p&lt;0.0001).<\/p>\n\n\n\n<p>Supported by these findings, Cogent plans to submit a New Drug Application (NDA) to the U.S. FDA for bezuclastinib in GIST during the first half of 2026 and will present complete trial data at a scientific conference in the same timeframe.<\/p>\n\n\n\n<p>The global, randomized Phase 3 PEAK study compared bezuclastinib plus sunitinib against sunitinib monotherapy in patients with imatinib-resistant or intolerant GIST. As of September 30, 2025, the data cutoff, the combination demonstrated a 50% reduction in the risk of disease progression or death compared to the standard of care (HR = 0.50, 95% CI: 0.39\u20130.65). Results confirmed an mPFS of 16.5 months for the combination versus 9.2 months for sunitinib alone, with an unprecedented ORR of 46% compared to 26%. At the time of reporting, overall survival (OS) data remain immature, but the average treatment duration for the bezuclastinib arm is projected to exceed 19 months.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-domain-therapeutics-doses-first-patients-in-phase-i-ii-trial-of-dt-7012-targeting-ccr8-in-solid-tumors\"><span class=\"ez-toc-section\" id=\"Domain_Therapeutics_Doses_First_Patients_in_Phase_III_Trial_of_DT-7012_Targeting_CCR8_in_Solid_Tumors\"><\/span><strong>Domain Therapeutics Doses First Patients in Phase I\/II Trial of DT-7012 Targeting CCR8 in Solid Tumors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Domain Therapeutics<\/strong> has announced that the first patients have been dosed in its <strong>Phase I\/II DOMISOL clinical study<\/strong> evaluating <strong>DT-7012<\/strong>, a differentiated Treg-depleting <a href=\"https:\/\/www.delveinsight.com\/report-store\/anti-c-c-motif-chemokine-receptor-8-antibodies-market-forecast\">anti-CCR8 monoclonal antibody<\/a>, for the treatment of advanced solid tumors.<\/p>\n\n\n\n<p>The DOMISOL study is an open-label, first-in-human trial focusing on the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of DT-7012. The trial is being conducted in Australia (NCT06819735).<\/p>\n\n\n\n<p>DT-7012 is designed to address a critical limitation of current cancer treatments, such as immune checkpoint inhibitors (ICIs), namely the immunosuppressive effect of <a href=\"https:\/\/www.delveinsight.com\/report-store\/regulatory-t-cells-tregs-market-forecast\">regulatory T cells (Tregs)<\/a> within the tumor microenvironment (TME). DT-7012 targets <strong>CCR8<\/strong>, a receptor predominantly expressed on these intratumoral Tregs.<\/p>\n\n\n\n<p>Domain Therapeutics highlights DT-7012&#8217;s unique, differentiated properties, stating it offers unprecedented selectivity in depleting these immunosuppressive Tregs via potent ADCC and ADCP mechanisms while simultaneously improving overall immune function. It is designed to maintain depletion efficiency even in challenging, CCL1-rich TMEs, positioning it as a potentially groundbreaking solution to overcome immune resistance in patients with limited options.<\/p>\n\n\n\n<p>This marks DT-7012 as Domain&#8217;s second fully proprietary asset to enter the clinic, underscoring the company&#8217;s ability to translate cutting-edge <strong>G Protein-Coupled Receptor (GPCR) biology<\/strong> into differentiated products. Domain Therapeutics specializes in targeting GPCRs, a crucial, yet often challenging, class of drug targets, for immuno-oncology and inflammatory diseases. The acquisition of this asset by Pfizer earlier this month, as previously reported, demonstrates the high market interest in this therapeutic area.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-anaptys-reports-phase-2-study-of-rosnilimab-in-moderate-to-severe-ulcerative-colitis-failed-to-achieve-primary-or-secondary-endpoints-at-week-12\"><span class=\"ez-toc-section\" id=\"Anaptys_Reports_Phase_2_Study_of_Rosnilimab_in_Moderate-to-Severe_Ulcerative_Colitis_Failed_to_Achieve_Primary_or_Secondary_Endpoints_at_Week_12\"><\/span><strong>Anaptys Reports Phase 2 Study of Rosnilimab in Moderate-to-Severe Ulcerative Colitis Failed to Achieve Primary or Secondary Endpoints at Week 12<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>AnaptysBio, Inc. <\/strong>reported that its investigational therapy <strong>rosnilimab <\/strong>was safe and well-tolerated but did not achieve the primary efficacy endpoint, mean change from baseline in the modified Mayo Score (mMS), or key secondary endpoints, including clinical response and remission at Week 12, in a global Phase 2 trial for <a href=\"https:\/\/www.delveinsight.com\/report-store\/ulcerative-colitis-uc-market\">moderate-to-severe ulcerative colitis<\/a>. Placebo response rates were consistent with historical data. As a result, the company will discontinue the UC trial, leading to estimated cost savings of at least $10 million.<\/p>\n\n\n\n<p>The Phase 2 randomized, double-blind, placebo-controlled, multicenter trial assessed rosnilimab\u2019s safety and efficacy in <strong>136 UC patients<\/strong> across the U.S. and Europe. Participants had a mean baseline mMS of 6.7 and had previously experienced inadequate response, loss of response, or intolerance to at least one conventional or advanced therapy. Around 50% had prior exposure to advanced treatments, and 62% had a Mayo Endoscopic Subscore (MES) of 3, indicating severe disease activity. Patients were randomized to receive 400 mg SC every four weeks (Q4W), 800 mg SC every two weeks (Q2W), or placebo.<\/p>\n\n\n\n<p>At Week 12, rosnilimab showed no efficacy advantage over placebo, with clinical remission achieved by 7% of patients in both dosing groups and endoscopic remission achieved by <strong>5% and 4%<\/strong>, respectively. Although early data indicated some improvement in remission rates between Weeks 12 and 24, the results at Week 24 did not meet the six-month target benchmarks.<\/p>\n\n\n\n<p>Consistent with findings from the <a href=\"https:\/\/www.delveinsight.com\/report-store\/rheumatoid-arthritis-ra-market\"><strong>rheumatoid arthritis Phase 2b trial<\/strong><\/a>, biomarker analyses demonstrated ~90% depletion of pathogenic T cells at Week 12, which was sustained through Week 24. During the treatment extension period (TEP), patients transitioned to a 400 mg every 8 weeks (Q8W) regimen and maintained these reductions up to Week 50. Moreover, PD-1+ T cells in colonic tissue were significantly depleted at Week 12, mirroring effects observed in synovial tissue from the RA study, with similar reductions across both induction doses, indicating maximal pharmacologic activity was achieved at 400 mg Q4W.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-evoke-pharma-enters-into-definitive-agreement-to-be-acquired-by-qol-medical\"><span class=\"ez-toc-section\" id=\"Evoke_Pharma_Enters_into_Definitive_Agreement_to_Be_Acquired_by_QOL_Medical\"><\/span><strong>Evoke Pharma Enters into Definitive Agreement to Be Acquired by QOL Medical<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Evoke Pharma, Inc.<\/strong>, a specialty pharmaceutical company, and QOL Medical, LLC, a privately held biopharmaceutical company, have entered a definitive agreement for <strong>QOL Medical to acquire Evoke for $11.00 per share in cash<\/strong>. The transaction, structured as a tender offer, has been unanimously approved by both Boards and is expected to close by the end of 2025.<\/p>\n\n\n\n<p>The purchase price of <strong>$11.00 per share<\/strong> represents a significant premium of <strong>139.7%<\/strong> to Evoke\u2019s closing share price on November 3, 2025. This valuation reflects the strategic importance of Evoke&#8217;s commercial product, <strong>GIMOTI (metoclopramide) nasal spray<\/strong>.<\/p>\n\n\n\n<p>GIMOTI is the first and only FDA-approved nasal spray formulation of metoclopramide indicated for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-gastroparesis-market-size\">treatment of acute and recurrent diabetic gastroparesis<\/a> in adults. Diabetic gastroparesis is a debilitating gastrointestinal disorder where gastric emptying is delayed, which can compromise the absorption of oral medications.<\/p>\n\n\n\n<p>QOL Medical CEO Derick Cooper noted the acquisition is a natural extension of their capabilities, strengthening their existing GI portfolio and establishing them as a leader in specialty gastrointestinal care. Evoke CEO Matt D\u2019Onofrio stated that QOL Medical is an ideal partner due to its strong commercial GI experience and commitment to continuity for the underserved diabetic gastroparesis community.<\/p>\n\n\n\n<p>The transaction is not subject to a financing condition and will be funded by QOL Medical using cash on hand. GIMOTI carries a <strong>Boxed Warning for Tardive Dyskinesia<\/strong>, a serious and often irreversible movement disorder, and treatment duration should be avoided for longer than 12 weeks.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-eledon-presents-phase-2-bestow-trial-results-for-tegoprubart-in-kidney-transplant-rejection-prevention-at-asn-kidney-week-2025\"><span class=\"ez-toc-section\" id=\"Eledon_Presents_Phase_2_BESTOW_Trial_Results_for_Tegoprubart_in_Kidney_Transplant_Rejection_Prevention_at_ASN_Kidney_Week_2025\"><\/span><strong>Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart in Kidney Transplant Rejection Prevention at ASN Kidney Week 2025<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Eledon Pharmaceuticals<\/strong> presented positive <strong>Phase 2 BESTOW trial <\/strong>results for <strong>tegoprubart<\/strong>, an <a href=\"https:\/\/www.delveinsight.com\/report-store\/cd40-cd40l-market\">anti-CD40L antibody<\/a>, for preventing organ rejection in <em>de novo<\/em> kidney transplant patients at the <strong>ASN Kidney Week 2025 Annual Meeting<\/strong>. The 12-month, randomized, head-to-head study compared tegoprubart-based immunosuppression (n = 63) with standard-of-care tacrolimus (n = 64).<\/p>\n\n\n\n<p>While the primary endpoint, change in eGFR at 12 months, did not reach statistical significance, the mean eGFR for tegoprubart was numerically higher, representing what Eledon believes is the highest reported mean eGFR in this setting. Subgroup analyses showed particularly high eGFRs for tegoprubart in living-related donor and high-KDPI recipient groups.<\/p>\n\n\n\n<p>The key finding was tegoprubart\u2019s differentiated and superior safety profile, which successfully avoided the chronic toxicities associated with tacrolimus:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Metabolic:<\/strong> New-onset diabetes after transplantation (NODAT) was significantly lower versus tacrolimus.<\/li>\n\n\n\n<li><strong>Neurologic:<\/strong> Tremor incidence was markedly lower.<\/li>\n\n\n\n<li><strong>Renal Recovery:<\/strong> Delayed graft function (DGF) occurred less often and required shorter dialysis time.<\/li>\n\n\n\n<li><strong>Infections:<\/strong> Sepsis\/bacteremia was also lower in the tegoprubart arm.<\/li>\n<\/ul>\n\n\n\n<p>Regarding efficacy, the drug met the FDA-recognized composite efficacy failure endpoint (death, graft loss, and acute rejection), demonstrating non-inferiority to tacrolimus. Based on these results, which highlight strong maintenance of renal function and substantially reduced long-term toxicities, Eledon plans to advance tegoprubart into Phase 3 development.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cogent Biosciences Announces Positive Outcomes from the Phase 3 PEAK Trial of Bezuclastinib in Gastrointestinal Stromal Tumors Cogent Biosciences, Inc. announced positive topline results from its Phase 3 PEAK trial evaluating bezuclastinib plus sunitinib in patients with imatinib-resistant or intolerant Gastrointestinal Stromal Tumors (GIST). The combination therapy achieved a median progression-free survival (mPFS) of 16.5 [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":33963,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[16553,22305,349,639,2019,22400,16410],"industry":[17225],"therapeutic_areas":[17239],"class_list":["post-33961","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-diabetic-gastroparesis","tag-gastrointestinal-stromal-tumors","tag-latest-pharma-news","tag-pharma-news","tag-rheumatoid-arthritis","tag-treg-cell-based-therapies","tag-ulcerative-colitis","industry-pharmaceutical","therapeutic_areas-gastroenterology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Cogent Biosciences, Anaptys, Eledon<\/title>\n<meta name=\"description\" content=\"Cogent Biosciences\u2019 Bezuclastinib; Domain Therapeutics\u2019 DT-7012; Anaptys\u2019 Rosnilimab; Eledon\u2019s Tegoprubart\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-cogent-biosciences-anaptys-eledon\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Cogent Biosciences, Anaptys, Eledon\" \/>\n<meta property=\"og:description\" content=\"Cogent Biosciences\u2019 Bezuclastinib; Domain Therapeutics\u2019 DT-7012; Anaptys\u2019 Rosnilimab; Eledon\u2019s Tegoprubart\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-cogent-biosciences-anaptys-eledon\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-11T09:54:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-11T09:54:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/11152424\/pharma-news-for-cogent-biosciences-anaptys-eledon.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Cogent Biosciences, Anaptys, Eledon","description":"Cogent Biosciences\u2019 Bezuclastinib; Domain Therapeutics\u2019 DT-7012; Anaptys\u2019 Rosnilimab; Eledon\u2019s Tegoprubart","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-cogent-biosciences-anaptys-eledon","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Cogent Biosciences, Anaptys, Eledon","og_description":"Cogent Biosciences\u2019 Bezuclastinib; Domain Therapeutics\u2019 DT-7012; Anaptys\u2019 Rosnilimab; Eledon\u2019s Tegoprubart","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-cogent-biosciences-anaptys-eledon","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-11-11T09:54:36+00:00","article_modified_time":"2025-11-11T09:54:38+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/11152424\/pharma-news-for-cogent-biosciences-anaptys-eledon.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-cogent-biosciences-anaptys-eledon","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-cogent-biosciences-anaptys-eledon","name":"Pharma News | Cogent Biosciences, Anaptys, Eledon","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-cogent-biosciences-anaptys-eledon#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-cogent-biosciences-anaptys-eledon#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/11152424\/pharma-news-for-cogent-biosciences-anaptys-eledon.webp","datePublished":"2025-11-11T09:54:36+00:00","dateModified":"2025-11-11T09:54:38+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Cogent Biosciences\u2019 Bezuclastinib; Domain Therapeutics\u2019 DT-7012; Anaptys\u2019 Rosnilimab; Eledon\u2019s Tegoprubart","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-cogent-biosciences-anaptys-eledon"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-cogent-biosciences-anaptys-eledon#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/11152424\/pharma-news-for-cogent-biosciences-anaptys-eledon.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/11152424\/pharma-news-for-cogent-biosciences-anaptys-eledon.webp","width":772,"height":482,"caption":"pharma-news-for-cogent-biosciences-anaptys-eledon"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/11152424\/pharma-news-for-cogent-biosciences-anaptys-eledon-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">diabetic gastroparesis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gastrointestinal Stromal Tumors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">rheumatoid arthritis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Treg Cell-based Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ulcerative colitis<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">diabetic gastroparesis<\/span>","<span class=\"advgb-post-tax-term\">Gastrointestinal Stromal Tumors<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">rheumatoid arthritis<\/span>","<span class=\"advgb-post-tax-term\">Treg Cell-based Therapies<\/span>","<span class=\"advgb-post-tax-term\">Ulcerative colitis<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 months ago","modified":"Updated 6 months ago"},"absolute_dates":{"created":"Posted on Nov 11, 2025","modified":"Updated on Nov 11, 2025"},"absolute_dates_time":{"created":"Posted on Nov 11, 2025 3:24 pm","modified":"Updated on Nov 11, 2025 3:24 pm"},"featured_img_caption":"pharma-news-for-cogent-biosciences-anaptys-eledon","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=33961"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33961\/revisions"}],"predecessor-version":[{"id":33962,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33961\/revisions\/33962"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/33963"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=33961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=33961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=33961"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=33961"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=33961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}